Thanks to the Global Pandemic, AI in Clinical Trials Is Here to Stay
In this special feature for PharmaVOICE’s October 2021 Showcase on AI, Saama’s Jonathan Burr, Senior VP, Clinical Platform Strategy, explains how biopharma has taken AI from tactical to transformational in the past year and a half.
Burr writes that “AI upended a clinical development process that had not changed dramatically for decades…The industry is leveraging AI to architect a new era of drug development that will result in faster clinical trials, broader patient engagement, greater physician participation, and more rapid delivery of effective therapies.”
The new paradigm is rewriting the clinical development handbook, and most biopharma companies know that there is no turning back.
